Trial · NCT01499511
Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study
NCT01499511, Completed, Imperial College London; results first posted 2019-12-03
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study. Trials, record NCT01499511. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01499511
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study
- NCT number
- NCT01499511
- Status
- Completed
- Enrollment
- 1,718 participants, actual
- Lead sponsor
- Imperial College London
- Conditions
- Hypertension, Diabetes, Death From Cardiovascular Disease, Myocardial Infarction, Stroke
- First posted
- 2011-12-26
- Last updated
- 2019-12-03
- Other registries' IDs
- eudract:2010-023875-24
- Results first posted
- 2019-12-03
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Who Have Died From Cardiovascular Disease Since the End of the ASCOT Study | 16 years | Number of participants who have died from cardiovascular disease since the end of the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Armstudy |
| Primary | Number of Participants With Non Fatal Myocardial Infarction | 16 years | Morbidity of non fatal myocardial infarction after 16 years in patients recruited into the Anglo-Scandinavian Outcomes trial with two groups |
| Primary | Number of Participants With Non Fatal Stroke/TIA (Transient Ischaemic Attack) | 16 years | Non fatal stroke and TIA (Transient Ischaemic Attack) morbidity after 16 years in patients recruited into the Anglo-Scandinavian Outcomes trial |
| Secondary | Number of Participants Who Have Developed Diabetes Since the End of the ASCOT Trial | 16 years | Diabetes morbidity after 16 years in patients recruited into the Anglo-Scandinavian Outcomes trial |
| Secondary | Number of Participants Who Have Undergone Coronary/Peripheral Re-vascularisation Procedures Since the End of the ASCOT Trial | 16 years | Number of participants who have undergone coronary/peripheral re-vascularisation procedures since the end of the ASCOT trial, follow up |
| Secondary | Number of Participants Who Have Required Renal Replacement Therapy (Dialysis or Kidney Transplant) Since the End of the ASCOT Trial | 16 years | Number of participants who have required renal replacement therapy (dialysis or kidney transplant) since the end of the ASCOT trial, follow up |
| Secondary | Number of Participants Who Have Experienced a Transient Ischaemic Attack (TIA) Since the End of the ASCOT Trial | 16 years |
Source ClinicalTrials.gov
Outcomes7
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants Who Have Died From Cardiovascular Disease Since the End of the ASCOT Study | 16 years | Data not collected | ||
| PRIMARY | Number of Participants With Non Fatal Myocardial Infarction | 16 years | 13 participants had missing data | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Non Fatal Stroke/TIA (Transient Ischaemic Attack) | 16 years | 18 participants had missing data | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Who Have Developed Diabetes Since the End of the ASCOT Trial | 16 years | 22 participants had missing data | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Who Have Undergone Coronary/Peripheral Re-vascularisation Procedures Since the End of the ASCOT Trial | 16 years | 24 participants had missing data | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Who Have Required Renal Replacement Therapy (Dialysis or Kidney Transplant) Since the End of the ASCOT Trial | 16 years | 18 participants had missing data | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Who Have Experienced a Transient Ischaemic Attack (TIA) Since the End of the ASCOT Trial | 16 years | Combined together with 3. primary outcome, it was not possible to differentiate between data collected for TIAs and Non fatal stroke |
Source ClinicalTrials.gov
Results by group10
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Non Fatal Myocardial Infarction | ASCOT Participants Amlodipine | 35 | Participants | ||
| Number of Participants With Non Fatal Myocardial Infarction | ASCOT Participants Atenolol | 37 | Participants | ||
| Number of Participants With Non Fatal Stroke/TIA (Transient Ischaemic Attack) | ASCOT Participants Amlodipine | 29 | Participants | ||
| Number of Participants With Non Fatal Stroke/TIA (Transient Ischaemic Attack) | ASCOT Participants Atenolol | 52 | Participants | ||
| Number of Participants Who Have Developed Diabetes Since the End of the ASCOT Trial | ASCOT Participants Amlodipine | 322 | Participants | ||
| Number of Participants Who Have Developed Diabetes Since the End of the ASCOT Trial | ASCOT Participants Atenolol | 325 | Participants | ||
| Number of Participants Who Have Undergone Coronary/Peripheral Re-vascularisation Procedures Since the End of the ASCOT Trial | ASCOT Participants Amlodipine | 39 | Participants | ||
| Number of Participants Who Have Undergone Coronary/Peripheral Re-vascularisation Procedures Since the End of the ASCOT Trial | ASCOT Participants Atenolol | 33 | Participants | ||
| Number of Participants Who Have Required Renal Replacement Therapy (Dialysis or Kidney Transplant) Since the End of the ASCOT Trial | ASCOT Participants Amlodipine | 10 | Participants | ||
| Number of Participants Who Have Required Renal Replacement Therapy (Dialysis or Kidney Transplant) Since the End of the ASCOT Trial | ASCOT Participants Atenolol | 9 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | ASCOT Participants Amlodipine | 885 | |
| Overall Study | STARTED | ASCOT Participants Atenolol | 833 | |
| Overall Study | COMPLETED | ASCOT Participants Amlodipine | 884 | |
| Overall Study | COMPLETED | ASCOT Participants Atenolol | 833 | |
| Overall Study | NOT COMPLETED | ASCOT Participants Amlodipine | 1 | |
| Overall Study | NOT COMPLETED | ASCOT Participants Atenolol | 0 |
Source ClinicalTrials.gov
Adverse events14
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Collapse | Nervous system disorders | ASCOT Participants Amlodipine | 0 | 885 | 0 |
| other | Collapse | Nervous system disorders | ASCOT Participants Atenolol | 1 | 833 | 1 |
| other | Bronchiectasis | Respiratory, thoracic and mediastinal disorders | ASCOT Participants Amlodipine | 1 | 885 | 1 |
| other | Bronchiectasis | Respiratory, thoracic and mediastinal disorders | ASCOT Participants Atenolol | 0 | 833 | 0 |
| other | Stomach cramps | Gastrointestinal disorders | ASCOT Participants Amlodipine | 1 | 885 | 1 |
| other | Stomach cramps | Gastrointestinal disorders | ASCOT Participants Atenolol | 0 | 833 | 0 |
| other | High blood pressure | Cardiac disorders | ASCOT Participants Amlodipine | 1 | 885 | 1 |
| other | High blood pressure | Cardiac disorders | ASCOT Participants Atenolol | 0 | 833 | 0 |
| other | Alcohol dependence withdrawal | Nervous system disorders | ASCOT Participants Amlodipine | 1 | 885 | 1 |
| other | Alcohol dependence withdrawal | Nervous system disorders | ASCOT Participants Atenolol | 0 | 833 | 0 |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | ASCOT Participants Amlodipine | 1 | 885 |
| Total, all-cause mortality | ASCOT Participants Atenolol | 0 | 833 |
| Total, other adverse events | ASCOT Participants Amlodipine | 4 | 885 |
| Total, other adverse events | ASCOT Participants Atenolol | 1 | 833 |
| Total, serious adverse events | ASCOT Participants Amlodipine | 2 | 885 |
| Total, serious adverse events | ASCOT Participants Atenolol | 0 | 833 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 16154016 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons7
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| ASCOT Participants Amlodipine vs ASCOT Participants Atenolol: Number of Participants Who Have Required Renal Replacement Therapy (Dialysis or Kidney Transplant) Since the End of the ASCOT Trial | Trial comparisons |
| ASCOT Participants Amlodipine vs ASCOT Participants Atenolol: Number of Participants Who Have Developed Diabetes Since the End of the ASCOT Trial | Trial comparisons |
| ASCOT Participants Amlodipine vs ASCOT Participants Atenolol: Number of Participants With Non Fatal Stroke/TIA (Transient Ischaemic Attack) | Trial comparisons |
| ASCOT Participants Amlodipine vs ASCOT Participants Atenolol: Number of Participants With Non Fatal Myocardial Infarction | Trial comparisons |
| ASCOT Participants Amlodipine vs ASCOT Participants Atenolol: Number of Participants Who Have Undergone Coronary/Peripheral Re-vascularisation Procedures Since the End of the ASCOT Trial | Trial comparisons |
| ASCOT Participants Amlodipine vs ASCOT Participants Atenolol: deaths from any cause | Trial comparisons |
| ASCOT Participants Amlodipine vs ASCOT Participants Atenolol: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01499511
GET https://conductscience.org/api/trials/v1/NCT01499511/registered